Therapeutic Advances in Childhood Leukemia Consortium
21
3
4
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
38.1%
8 terminated/withdrawn out of 21 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
200%
16 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Role: lead
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy
Role: lead
Epigenetic Reprogramming in Relapse/Refractory AML
Role: lead
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Role: lead
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
Role: lead
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Role: lead
Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.
Role: lead
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Role: lead
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Role: collaborator
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Role: lead
Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML
Role: lead
AC220 for Children With Relapsed/Refractory ALL or AML
Role: lead
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Role: lead
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Role: lead
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
Role: lead
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Role: lead
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Role: lead
Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
Role: lead
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
Role: lead
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
Role: lead